MARC record from Internet Archive

LEADER: 05026cam 2200637 a 4500
001 ocm30475324
003 OCoLC
005 20100825143410.0
008 940429s1994 nyua b 001 0 eng
010 $a 94012572
040 $aDLC$cDLC$dEXR$dJBO$dPIT$dVET$dSDA$dBAKER$dNLGGC$dBTCTA$dYDXCP$dOCLCG$dUAB
020 $a0312114869
020 $a9780312114862
035 $a(OCoLC)30475324
050 00 $aRC483.5.F55$bB75 1994
082 00 $a615/.78$220
084 $a44.91$2bcl
096 $aQV 77.5 B833 1994
100 1 $aBreggin, Peter Roger,$d1936-
245 10 $aTalking back to prozac :$bwhat doctors won't tell you about today's most controversial drug /$cPeter R. Breggin and Ginger Ross Breggin.
250 $a1st ed.
260 $aNew York :$bSt. Martin's Press,$c1994.
300 $axiv, 273 p. :$bill. ;$c22 cm.
504 $aIncludes bibliographical references (p. [241]-263) and index.
505 0 $aShould we listen to Prozac? -- A primer on how Prozac is supposed to work -- The real story behind Prozac's approval by the FDA -- The real story behind Prozac's side effects -- Drug addiction and abuse: a comparison between Prozac and amphetamines -- Drug-induced paranoia, violence, depression, and suicide: a comparison between Prozac and amphetamines -- Can Prozac cause violence and suicide? what survivors, independent researchers, and the FDA have to say -- Pushing drugs in America: the long financial tentacles of Eli Lilly -- How and why to stop taking psychiatric drugs -- Understanding and overcoming depression.
520 $aProzac. Millions of Americans are on it. And just about everyone else is wondering if they should be on it, too. The claims of the pro-Prozac chorus are enticing: that it can cure everything from depression (the only disorder for which Prozac was originally approved) to fear of public speaking, PMS, obesity, shyness, migraine, and back pain - with few or no side effects. But is the reality quite different? At what price do we buy Prozac-induced euphoria and a shiny new personality?
520 8 $aPsychiatrist Peter Breggin, M.D., and coauthor Ginger Ross Breggin answer these and other crucial questions in Talking Back to Prozac. They explain what Prozac is and how it works.
520 8 $aAnd they take a hard look at the real story behind today's most controversial drug: the fact that Prozac was tested in trials of four to six weeks in length before receiving FDA approval; the difficulty Prozac's manufacturer had in proving its effectiveness during these tests; the information on side effects that the FDA failed to include in its final labeling requirements; how Prozac acts as a stimulant not unlike the addictive drugs cocaine and amphetamine; the dangers of possible Prozac addiction and abuse; the seriousness and frequency of Prozac's side effects, including agitation, insomnia, nausea, diarrhea, loss of libido, and difficulty reaching orgasm; the growing evidence that Prozac can cause violence and suicide; and the social and workplace implications of using the drug not to cure depression but to change personality and enhance performance.
520 8 $aUsing dramatic case histories as well as scientific research and carefully documented evidence, the Breggins expose the potentially damaging effects of Prozac. They also describe the resounding success that has been achieved with more humane alternatives for the treatment of depression. Talking Back to Prozac provides essential information for anyone who takes Prozac or is considering taking it, and for those who prescribe it.
650 0 $aFluoxetine$xMoral and ethical aspects.
650 0 $aFluoxetine$xSocial aspects.
650 0 $aFluoxetine$xSide effects.
650 0 $aPersonality change.
650 0 $aAntipsychiatry.
650 2 $aFluoxetine$xadverse effects.
650 2 $aPersonality Disorders$xchemically induced.
650 17 $aPsychofarmaca.$2gtt
700 1 $aBreggin, Ginger Ross.
938 $aBaker & Taylor$bBKTY$c19.95$d14.96$i0312114869$n0002467119$sactive
938 $aBaker and Taylor$bBTCP$n94012572
938 $aYBP Library Services$bYANK$n186733
952 $a30475324$zDLC$bLIBRARY OF CONGRESS$hFull$iLCC$kDDC$nSummary$tContents$u20091102
952 $a130766813$zYUS$bYALE UNIV LIBR$hFull$iLCC$kDDC$u20100705
952 $a132629601$zJTC$bSHASTA PUB LIBR$hFull$iLCC$kDDC$u20100709
952 $a134896255$zRBN$bBROWN UNIV$hFull$iLCC$kDDC$u20100702
952 $a189672247$zPAU$bUNIV OF PENNSYLVANIA$hFull$iLCC$kDDC$u20100703
952 $a241335684$zHLS$bHARVARD UNIV, HARVARD COL LIBR$hFull batch$iLCC$kDDC$u20100710
952 $a369094069$zUBY$bBRIGHAM YOUNG UNIV LIBR$hFull$iLCC$kDDC$u20100713
952 $a484535608$zN15$bNEW YORK UNIV, GROUP BATCHLOAD$hFull$iLCC$kDDC$u20100705
029 1 $aNLGGC$b119353784
029 1 $aYDXCP$b186733
029 1 $aNZ1$b4615742
029 1 $aAU@$b000021611005
029 1 $aAU@$b000010942250
994 $aZ0$bPMR
948 $hNO HOLDINGS IN PMR - 682 OTHER HOLDINGS